Las Vegas, USA, Oct. 27, 2021 (GLOBE NEWSWIRE) -- DelveInsight Analyzes a Thriving Cutaneous Lupus Erythematosus Pipeline in the Coming Years as Key Pharma Companies Enter the...
BMY set a new low on uninspiring guidance. SLAB hit a new high. Solar stocks rose on strong earnings from ENPH. CRTX plunged on weak clinical trial results. NRIX climbed on strong...
Adding to the recent losses, the shares of Bristol-Myers Squibb have reached a 52-week low despite better-than-expected financials posted by the company for Q3 2021
Base your stock investment decisions on fundamental values rather than short-term price activity.
I am bullish on Bristol Myers Squibb (BMY) because its valuation multiples indicate that it trades at a discount to its fair value based on past history. Furthermore, its dividend...
The global pharmaceutical market has experienced significant growth in recent years. As of end-2020, the total global pharmaceutical market was valued at about 1.27 trillion U.S....
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Technical Indicators | Sell | Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,002.00 | 2,070.00 | 1,982.00 | +14.00 | +0.70% | 496.46K | London | |||
| 1,875.00 | 1,850.00 | 1,850.00 | 0.00 | 0.00% | 0.00 | London | |||
| 102.90 | 110.00 | 102.90 | -2.10 | -2.00% | 358.45K | London | |||
| 360.10 | 365.55 | 357.35 | -9.80 | -2.65% | 46.51M | London | |||
| 133.92 | 135.30 | 133.50 | -1.04 | -0.77% | 16.30M | London | |||
| 476.00 | 487.00 | 476.00 | -7.00 | -1.45% | 1.05M | London | |||
| 48.00 | 48.80 | 47.85 | +1.00 | +2.13% | 356.72K | London | |||
| 60.40 | 60.60 | 59.40 | +1.14 | +1.92% | 12.29M | London | |||
| 117.20 | 119.20 | 116.20 | +0.40 | +0.34% | 1.78M | London | |||
| 449.50 | 458.50 | 447.00 | -6.50 | -1.43% | 189.59K | London | |||
| 15.60 | 15.60 | 15.20 | +0.10 | +0.65% | 354.05K | London | |||
| 34.00 | 35.00 | 33.50 | -0.50 | -1.45% | 774.42K | London | |||
| 4.85 | 4.85 | 4.85 | 0.0000 | 0.00% | 136.63K | London | |||
| 637.80 | 645.00 | 635.20 | -8.40 | -1.30% | 1.12M | London | |||
| 7.55 | 7.55 | 7.55 | -0.10 | -1.31% | 284.81K | London |
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abraxane, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Reyataz and Sustiva Franchise. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.